Why this Dallas biotech firm is cutting roughly 35% of its headcount

The firm hopes the move will extend Its cash runway to the fourth quarter of 2023.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.